A randomized, double-blind, placebo-controlled, parallel-group study to investigate the | C4C
This clinical trial is a commercial trial developed and headed by Janssen. It aims to investigate the safety and usefulness of a proposed new drug for the treatment of Major Depressive Disorder (MDD). It will recruit approximately 64 patients with MDD. Our site will act as a Patient Recruitment Centre (‘PIC’), identifying potentially suitable Participants at the South London and Maudsley (SLaM) and approaching them about this study if they have given consent for contact (C4C). Informed Consent for the trial and trial-specific events will take place at The Surrey Sleep Research Centre (SSRC) or Hammersmith Medicines Research (HMRLondon) both of which are specialist research centres accredited by the Medicines and Health Care Regulatory Agency (MHRA) for conducting this type of trial. SSRC and HMRLondon have the necessary facilities to conduct this trial which involves special analysis of sleep.